Myriad Genetics PT Lowered to $26.00 (MYGN)
Investment analysts at Credit Suisse cut their target price on shares of Myriad Genetics (NASDAQ: MYGN) from $28.00 to $26.00 in a note issued to investors on Friday. The firm currently has a “neutral” rating on the stock.
Myriad Genetics (NASDAQ: MYGN) traded down 0.15% on Friday, hitting $25.90. Myriad Genetics has a 52-week low of $22.02 and a 52-week high of $31.80. The stock’s 50-day moving average is currently $25.61. The company has a market cap of $2.087 billion and a price-to-earnings ratio of 17.78.
Myriad Genetics (NASDAQ: MYGN) last announced its earnings results on Tuesday, February 5th. The company reported $0.42 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.38 by $0.04. The company had revenue of $140.70 million for the quarter, compared to the consensus estimate of $143.71 million. During the same quarter in the prior year, the company posted $0.33 earnings per share. The company’s quarterly revenue was up 19.6% on a year-over-year basis. Myriad Genetics has set its FY13 guidance at $1.55-1.58 EPS. Analysts expect that Myriad Genetics will post $1.58 EPS for the current fiscal year.
MYGN has been the subject of a number of other recent research reports. Analysts at Zacks reiterated an “outperform” rating on shares of Myriad Genetics in a research note to investors on Tuesday, March 5th. They now have a $30.00 price target on the stock. Separately, analysts at Jefferies & Co. cut their price target on shares of Myriad Genetics from $33.00 to $31.00 in a research note to investors on Monday, March 4th. They now have a “buy” rating on the stock. Finally, analysts at Oppenheimer cut their price target on shares of Myriad Genetics from $31.00 to $29.00 in a research note to investors on Monday, March 4th. They now have a “market perform” rating on the stock.
Nine investment analysts have rated the stock with a buy rating, eight have assigned a hold rating, and one has assigned a sell rating to the company’s stock. The company currently has a consensus rating of “overweight” and an average price target of $29.82.
Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.